FindTrial
Sign In

The efficacy of DEB-TACE and c-TACE in the treatment of intrahepatic cholangiocarcinoma: a real world study

The efficacy of DEB-TACE and c-TACE in the treatment of intrahepatic cholangiocarcinoma: a real world study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900024019
Enrollment
Unknown
Registered
2019-06-22
Start date
2019-07-01
Completion date
Unknown
Last updated
2019-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intrahepatic cholangiocarcinoma,ICC

Interventions

c-TACE:DEB-TACE

Sponsors

Shengjing Hospital of China Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. The subject or his or her legal guardian is willing and able to provide informed consent and sign an informed consent form; 2. Aged 18 to 75 years old; 3. All patients were confirmed as intrahepatic cholangiocarcinoma by biopsy; 4. Patients with a tumor that was first diagnosed or relapsed after surgery or radiofrequency ablation.

Exclusion criteria

Exclusion criteria: 1. previous history of radiotherapy and chemotherapy and arterial embolization; 2. Child-Pugh C; 3. ECOG score>1.

Design outcomes

Primary

MeasureTime frame
Progression-Free Survival ;OS;—

Countries

China

Contacts

Public ContactChang Zhihui

Shengjing Hospital of China Medical University

changzh@sj-hospital.org+86 18940258437

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026